Partner Headlines - TEVA

  1. Top 5 Earnings Reports To Watch After The Close Tue.

    IBD
  2. Pfizer, Merck, Amgen Near Q2 Earnings Reports

    IBD
  3. George Soros Reveals His Largest Stake

    GuruFocus
  4. Sofinnova Ventures Closes $500M Fund

    FoxBusiness
  5. Israel's Market Appears Unfazed By Rising Conflict

    IBD
  6. George Soros Keeps Buying TEVA, EQT, YPF, EGN, CZR And Keeps ...

    GuruFocus
  7. UPDATE: Teva Announces FDA Acceptance of NDA For Inhaler

    Benzinga
  8. 4 Top Performing Health Care Stocks With More Potential Upside

    Benzinga
  9. Salix, Akorn, Regeneron Lead Drug Stock Rally

    IBD
  10. Top 4 Stocks In The Drug Manufacturers-Other Industry With The ...

    Benzinga
  11. Diamond Hill Capital Comments on Teva Pharmaceutical Industries ...

    GuruFocus
  12. Diamond Hill Select Fund Commentary - First Quarter 2014

    GuruFocus
  13. Teva Pharmaceutical

    IBD
  14. Generic-Drug Makers Climb Ranks; Several In Buy Range

    IBD
  15. Teva Turmoil: Shares Up, Board Trimmed, CEO To Retire

    Benzinga
  16. Wells Fargo Initiates Coverage On The Pharmaceutical Space

    Benzinga
  17. Top Guru Held Asian Companies of the First Quarter

    GuruFocus
  18. Teva to buy Labrys Biologics

    IBD
  19. Chicago sues painkiller firms

    IBD
  20. Benzinga's M&A Chatter for Tuesday June 3, 2014

    Benzinga
  21. Teva Acquiring Labrys Biologics For Migraine Drug

    IBD
  22. Richard Snow's Top Five Highlight Finance and Healthcare Sectors

    GuruFocus
  23. Benzinga's M&A Chatter for Wednesday May 7, 2014

    Benzinga
  24. ETF Outlook For Tuesday May 6, 2014 (EUFN, ITA, EIS, UAE)

    Benzinga
  25. Wrong Marketing Lesson by Big Pharma

    GuruFocus
  26. Sterne Agee Sees Mixed Factors For Teva Pharmaceutical Industries ...

    Benzinga
  27. Teva EPS tops; rivals seen?

    IBD
  28. Market Wrap For May 1: Markets Mixed To Start The New Month

    Benzinga
  29. Earnings Scheduled For May 1, 2014

    Benzinga
  30. Actavis Beats Q1 Views, Looks To Supersized Future

    IBD
  31. Actavis Reporting Q1 Earnings Amid Merger Frenzy

    IBD
  32. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  33. Morning Market Losers

    Benzinga
  34. Benzinga's Top #PreMarket Losers

    Benzinga
  35. UPDATE: Teva, Oncogenex Offer Top-Line Survival Results of Phase ...

    Benzinga
  36. Nasdaq Could Be in for a Bounce

    FoxBusiness
  37. Actavis got a Pfizer

    IBD
  38. Teva Settles Patent Litigation with Pfizer on Celebrex; Has Received ...

    Benzinga
  39. Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing

    Benzinga
  40. Teva Unveils Generic Lunesta Tablets in US

    Benzinga
  41. Teva Announces First Approval and Launch of Generic Lovaza® Capsules ...

    Benzinga
  42. Market Wrap For April 7: Bears In Complete Control As Markets ...

    Benzinga
  43. Citigroup Slaps $70 Price Target on Teva, Highest on Street

    Benzinga
  44. Market Wrap For March 31: Stocks Rally As Yellen Confirms Support ...

    Benzinga
  45. Analyst Offers Insight on Favorable FDA Ruling for Teva Pharma

    Benzinga
  46. Market Wrap For March 28: Markets Still Positive Despite Giving ...

    Benzinga
  47. Teva Offers Most Attractive Risk-Reward Profile, Citigroup Says

    Benzinga
  48. UPDATE: Goldman Sachs Upgrades Teva Pharmaceutical Industries

    Benzinga
  49. Forest Laboratories' Recovery

    GuruFocus
  50. Should You Buy Actavis?

    GuruFocus
  51. Horizon Pharma Banks On Two-For-One Arthritis Drugs

    IBD
  52. UPDATE: JP Morgan Upgrades Teva Pharmaceuticals

    Benzinga
  53. UPDATE: Morgan Stanley Upgrades Teva Pharmaceutical Industries ...

    Benzinga
  54. Benzinga's Top Upgrades

    Benzinga
  55. US Stock Futures Edge Higher Ahead Of Consumer Sentiment Report

    Benzinga
  56. Pfizer Loses Patent On Celebrex, Plans To Appeal

    IBD
  57. Pfizer Loses Bid to Hold Celebrex Exclusivity to '15

    FoxBusiness
  58. Will Horizon Pharma Spike Again On Quarterly Report?

    IBD
  59. UPDATE: Barclays Upgrades Teva Pharmaceutical Industries Limited ...

    Benzinga
  60. Teva upgraded on drug launch

    IBD
  61. Teva Upgraded On Strong Launch Of Next-Gen Copaxone

    IBD
  62. Weekly 52-Week Highs Highlight: COV, EQT, XLNX, TEVA

    GuruFocus
  63. UPDATE: CRT Capital Initiates Coverage on OncoGenex

    Benzinga
  64. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With ...

    Benzinga
  65. Insys Recovers From Stock Hit Tied To Fed Probe

    IBD
  66. Generic-Drug Makers Actavis, Mylan To Report Q4 Soon

    IBD
  67. #PreMarket Primer: Friday, February 7: Jobs Friday

    Benzinga
  68. Teva Pharmaceuticals A Giant In Generic Drugs

    IBD
  69. UPDATE: Teva Pharmaceutical Posts Upbeat Q4 Earnings

    Benzinga
  70. Earnings Scheduled For February 6, 2014

    Benzinga
  71. Market Wrap For January 29: Markets Lower on Fed Taper, Emerging ...

    Benzinga
  72. Stocks Hitting 52-Week Highs

    Benzinga
  73. Special Situations Alert: Details Behind Why I Bought PATH

    GuruFocus
  74. Teva, Active Biotech Say Remain Committed to Development of NERVENTRA

    Benzinga
  75. Benzinga's M&A Chatter for Tuesday January 21, 2014

    Benzinga
  76. NuPathe Terminates Agreement With Endo Pharma and Enters Into ...

    Benzinga
  77. US Stock Futures Up; Alcoa Earnings, Jobless Claims Data In Focus

    Benzinga
  78. Drug Mergers Queuing Up

    IBD
  79. Forest Buying Aptalis; Teva Bids For NuPathe Vs. Endo

    IBD
  80. Morning Market Movers

    Benzinga
  81. Benzinga's Top #PreMarket Gainers

    Benzinga
  82. Market Wrap For January 2: Markets Begin 2014 on Negative Note

    Benzinga
  83. Groups of Gurus Trade Ten-Year Low P/B Stocks - CLH, IMO and ...

    GuruFocus
  84. Market Wrap For December 27: Markets Quiet Before Weekend

    Benzinga
  85. Biologic Makers Thwart Generics: Winning Stocks

    YCharts
  86. Morning Market Movers

    Benzinga
  87. Benzinga's Top #PreMarket Gainers

    Benzinga
  88. Stocks To Watch For December 27, 2013

    Benzinga
  89. ANI Pharma Buys 31 Generic Drug Products from Teva for $12.5M ...

    Benzinga
  90. Teva Pharmaceuticals

    IBD
  91. Pfizer Settles Viagra Patent Litigation With Teva

    Benzinga
  92. Why Pfizer’s Expiring Viagra Patent Hurts Lilly Most

    YCharts
  93. Teva Pharmaceutical

    IBD
  94. Teva, Takeda Announce Agreement for Glatiramer Acetate for MSTreatment ...

    Benzinga
  95. Top Five Guru-Held Asian Companies as of the Third Quarter

    GuruFocus
  96. ETF Outlook for the week of December 2, 2013

    Benzinga
  97. Wide Range of ETFs Hitting New Highs (EWN, NLR, EIS, ING, TEVA)

    Benzinga
  98. Teva, Mylan Settle Copaxone Patent Litigation in France, UK, ...

    Benzinga
  99. Teva Says Company Guidance Published in The Maker is Outdated ...

    Benzinga
  100. 2013 3Q 13F Roundup

    Benzinga
Trading Center